Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI 1181181 in Young Healthy Male Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Groups Phase I Trial)

Trial Profile

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI 1181181 in Young Healthy Male Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Groups Phase I Trial)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 23 Jul 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BI 1181181 (Primary)
  • Indications Alzheimer's disease
  • Focus Biomarker; Pharmacodynamics
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 12 Nov 2014 Results published in Vitae Pharmaceuticals media release.
    • 23 Oct 2014 Primary endpoint has been met (% change from baseline of beta amyloid protein 1-40 in cerebrospinal fluid at 24 hrs post dose), according to a Vitae Pharmaceuticals media release.
    • 23 Oct 2014 Top-line results published in a Vitae Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top